TransCode Therapeutics, Inc. (RNAZ) DCF Valuation

TransCode Therapeutics, Inc. (RNAZ) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

TransCode Therapeutics, Inc. (RNAZ) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess the intrinsic value of TransCode Therapeutics, Inc.? Our RNAZ DCF Calculator integrates real-world data with extensive customization features, enabling you to refine forecasts and enhance your investment strategies.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA .0 .0 -6.1 -17.5 -18.0 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .5 .7 .0 .1 .5 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -.5 -.7 -6.2 -17.6 -18.5 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash .2 .8 20.8 5.0 2.8 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .4 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .6 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .0 .0 2.0 4.3 .0 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 -.3 -.1 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -.6 -.8 -6.2 -35.1 -18.5 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -.1 -.1 -4.4 -33.7 -21.4 .0 .0 .0 .0 .0
WACC, % 9.02 9.02 9.02 9.02 9.02 9.02 9.02 9.02 9.02 9.02
PV UFCF
SUM PV UFCF .0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 0
Net Debt -2
Equity Value 2
Diluted Shares Outstanding, MM 0
Equity Value Per Share 12.94

What You Will Get

  • Pre-Filled Financial Model: TransCode Therapeutics, Inc. (RNAZ) provides actual data for accurate DCF valuation.
  • Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
  • Instant Calculations: Automatic updates ensure you see results in real-time as you make adjustments.
  • Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
  • Customizable and Reusable: Designed for adaptability, enabling ongoing use for comprehensive forecasts.

Key Features

  • Comprehensive Data: TransCode Therapeutics' historical financial statements and pre-filled projections.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Results: Monitor TransCode's intrinsic value recalculating instantly.
  • Intuitive Visual Outputs: Dashboard charts illustrate valuation results and essential metrics.
  • Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.

How It Works

  • Step 1: Download the prebuilt Excel template featuring TransCode Therapeutics, Inc. (RNAZ) data.
  • Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see the recalculated results, including TransCode Therapeutics, Inc.'s (RNAZ) intrinsic value.
  • Step 5: Make well-informed investment decisions or create reports based on the generated outputs.

Why Choose TransCode Therapeutics, Inc. (RNAZ)?

  • Innovative Solutions: Pioneering RNA-based therapies that target unmet medical needs.
  • Expertise in RNA Technology: A dedicated team with extensive experience in RNA therapeutics enhances reliability.
  • Robust Research Pipeline: A diverse array of projects aimed at transforming cancer treatment.
  • Commitment to Quality: Rigorous testing and validation processes ensure high standards in all developments.
  • Industry Recognition: A trusted name among investors and healthcare professionals in the biopharmaceutical sector.

Who Should Use This Product?

  • Biotech Investors: Develop comprehensive and accurate valuation models for assessing RNAZ investments.
  • Corporate Strategy Teams: Evaluate valuation scenarios to inform strategic decisions within the biotech sector.
  • Consultants and Advisors: Deliver precise valuation insights for clients interested in TransCode Therapeutics (RNAZ).
  • Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling related to biotech.
  • Pharmaceutical Enthusiasts: Gain insights into how biotech companies like TransCode Therapeutics (RNAZ) are valued in the market.

What the Template Contains

  • Historical Data: Includes TransCode Therapeutics, Inc.'s (RNAZ) past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate TransCode Therapeutics, Inc.'s (RNAZ) intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of TransCode Therapeutics, Inc.'s (RNAZ) financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.